Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CFMS

Conformis (CFMS) Stock Price, News & Analysis

Conformis logo

About Conformis Stock (NASDAQ:CFMS)

Advanced Chart

Key Stats

Today's Range
$2.25
$2.27
50-Day Range
$2.22
$2.26
52-Week Range
$1.05
$7.25
Volume
7,000 shs
Average Volume
99,585 shs
Market Capitalization
$17.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CFMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter.

CFMS Stock News Headlines

Conformis (NASDAQ: CFMS)
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
CFM Investment JSC CFM
Computer Forms (Malaysia) Bhd (CFMS)
Durham medtech completes acquisition of public company
See More Headlines

CFMS Stock Analysis - Frequently Asked Questions

Conformis, Inc. (NASDAQ:CFMS) announced its quarterly earnings results on Wednesday, November, 3rd. The medical instruments supplier reported ($1.75) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.75). The medical instruments supplier had revenue of $14.25 million for the quarter, compared to analysts' expectations of $14.08 million. Conformis had a negative trailing twelve-month return on equity of 86.46% and a negative net margin of 72.72%.
Read the conference call transcript
.

Conformis's stock reverse split on Wednesday, November 9th 2022.The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Conformis (CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Conformis investors own include Meta Platforms (META), Micron Technology (MU), NIO (NIO), NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/03/2021
Today
7/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
NASDAQ:CFMS
CIK
1305773
Employees
295
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($5.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$50.47 million
Net Margins
-72.72%
Pretax Margin
-72.63%
Return on Equity
-86.46%
Return on Assets
-47.65%

Debt

Debt-to-Equity Ratio
0.64
Current Ratio
5.07
Quick Ratio
3.30

Sales & Book Value

Annual Sales
$57.06 million
Price / Sales
0.31
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.07 per share
Price / Book
0.56

Miscellaneous

Outstanding Shares
7,878,000
Free Float
7,579,000
Market Cap
$17.80 million
Optionable
Not Optionable
Beta
1.39

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:CFMS) was last updated on 7/21/2025 by MarketBeat.com Staff
From Our Partners